On this page
Carney complex type 1
This autosomal dominant disorder results from pathogenic variants in the PRKAR1A gene and typically presents with a distinctive pattern of pigmented skin lesions, cardiac tumours called myxomas, and overactive endocrine glands. The condition affects multiple body systems and requires coordinated surveillance throughout life.
Overview
Carney complex type 1 represents a rare tumour predisposition syndrome in which affected individuals develop benign growths across multiple organ systems. The hallmark features include skin pigmentation abnormalities, tumours of the heart and endocrine organs, and distinctive spotty freckling particularly around the lips, eyes, and genital areas. Research suggests that most individuals with this condition carry a pathogenic variant in the PRKAR1A gene, which disrupts normal cellular growth regulation [PMID:11101837].
The condition typically becomes apparent during childhood or young adulthood, though the specific combination and timing of features varies considerably between affected individuals. Some people develop only subtle skin changes, whilst others experience significant endocrine complications requiring medical intervention. The name honours J. Aidan Carney, who first described the clinical pattern in detail during the 1980s. Exact prevalence figures for the UK population are not well established, though the condition is considered rare with fewer than 750 reported families worldwide [PMID:16825433].
Symptoms & clinical features
Clinical features of Carney complex type 1 emerge gradually, often beginning with characteristic skin changes during childhood. The most distinctive finding involves lentigines - small, dark spots measuring 1-5 millimetres that appear on the face, particularly the lips and eyelids, as well as the conjunctiva and genital mucosa. These pigmented lesions tend to increase in number with age and differ from ordinary freckles by appearing in unusual locations and having irregular borders.
Endocrine manifestations represent the most clinically significant aspect of this condition. Primary pigmented nodular adrenocortical disease affects a substantial proportion of individuals, causing overproduction of cortisol and features of Cushing's syndrome including weight gain, high blood pressure, and characteristic changes in body fat distribution [PMID:11101837]. Some individuals develop growth hormone-producing pituitary tumours, potentially causing acromegaly with enlargement of the hands, feet, and facial features. Thyroid nodules and testicular tumours also develop in some affected individuals. Cardiac myxomas - gelatinous tumours within the heart chambers - represent a significant feature and may cause symptoms including breathlessness, palpitations, or stroke-like episodes if fragments break away and travel through the bloodstream.
Video: Genetics 101
Affected organs
The condition affects multiple body systems, though the endocrine glands and cardiovascular system bear the greatest clinical burden. Within the endocrine system, the adrenal glands show particularly striking changes, developing numerous small pigmented nodules that gradually replace normal tissue and produce excess cortisol. The pituitary gland may harbour growth hormone-secreting adenomas, whilst the thyroid frequently develops multiple nodules. In males, large cell calcifying Sertoli cell tumours of the testes represent a characteristic feature, though these are typically benign.
The heart represents another major target organ, with myxomas developing within any of the four cardiac chambers. These tumours may recur even after surgical removal, necessitating ongoing surveillance. The skin shows widespread pigmentary changes, whilst some individuals develop distinctive skin myxomas - small, flesh-coloured or pink nodules. Other tissues occasionally affected include mammary tissue, where fibroadenomas and other benign tumours may develop, and peripheral nerves, which can give rise to schwannomas [PMID:16825433].
Risks & severity
The severity of Carney complex type 1 varies substantially between affected individuals, even within the same family. Some people experience only cosmetic concerns from skin pigmentation, whilst others develop life-threatening complications from cardiac myxomas or severe endocrine dysfunction. Evidence suggests that cardiac myxomas represent the most serious acute risk, as these tumours can obstruct blood flow through the heart or cause embolic strokes if tumour fragments enter the circulation.
Endocrine complications typically develop more gradually but may significantly impact quality of life. Cushing's syndrome from adrenal disease often emerges during childhood or adolescence and can affect growth and development if not recognised and treated. The lifetime risk of developing clinically significant endocrine tumours appears substantial in individuals carrying PRKAR1A variants, though precise figures remain uncertain due to the rarity of the condition. Regular surveillance enables detection of cardiac and endocrine tumours before they cause serious complications in most cases.
Genetic causes
Carney complex type 1 results from pathogenic variants in PRKAR1A, which encodes the type 1-alpha regulatory subunit of protein kinase A. This enzyme complex plays a fundamental role in cellular signalling, particularly in pathways that control cell growth, division, and hormone production. Under normal circumstances, the regulatory subunit keeps protein kinase A inactive until specific molecular signals trigger its release, allowing controlled cellular responses to hormones and growth factors.
Pathogenic changes in PRKAR1A typically result in reduced production of functional regulatory protein, disrupting the normal brake on protein kinase A activity. This leads to excessive and inappropriate cellular proliferation in susceptible tissues, particularly those responsive to hormonal signals [PMID:11101837]. The majority of disease-causing variants are loss-of-function changes - deletions, nonsense variants, or frameshift alterations that prevent production of stable protein. The affected tissues in Carney complex largely correspond to organs where cyclic AMP signalling and protein kinase A play important regulatory roles, explaining the characteristic distribution of tumours across endocrine and cardiac tissues [PMID:16825433].
- PRKAR1A protein kinase cAMP-dependent type I regulatory subunit alphaThe PRKAR1A gene provides instructions for a regulatory subunit of protein kinase A (PKA), an enzyme essential for controlling cell growth and division within the body.
Inheritance pattern
Carney complex type 1 follows an autosomal dominant pattern of inheritance, meaning a single pathogenic variant in one copy of PRKAR1A is sufficient to cause the condition. An affected parent has a 50% chance of passing the variant to each child, regardless of the child's sex. However, the specific features and their severity can differ markedly between family members carrying the same genetic change, a phenomenon called variable expressivity.
The majority of individuals with Carney complex have an affected parent, whilst the remaining cases result from de novo variants - new genetic changes occurring for the first time in that individual. When a person with Carney complex has children, each child faces a 50% risk of inheriting the condition. Genetic counselling helps families understand these inheritance patterns and the implications for relatives, including options for predictive testing in at-risk family members.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
Diagnosis & testing
Diagnosis of Carney complex type 1 relies on recognising the characteristic clinical pattern, often supplemented by genetic testing. Clinical diagnostic criteria require either two major features (such as cardiac myxoma, skin pigmentation in typical distribution, endocrine tumours, or myxomatous skin tumours) or one major feature plus a confirmed pathogenic PRKAR1A variant. Additional supporting features include a first-degree relative with confirmed Carney complex.
Genetic testing through the NHS Genomic Medicine Service can identify PRKAR1A variants in many individuals meeting clinical criteria, though some affected families carry variants in other genes or have changes not detectable by standard testing methods. Testing typically uses next-generation sequencing panels that include PRKAR1A alongside other tumour predisposition genes. Referral to clinical genetics services occurs through various routes - endocrinologists may refer patients presenting with unusual adrenal disease, cardiologists may refer following myxoma diagnosis, or dermatologists may recognise the distinctive pigmentation pattern. The relevant NHS R-code is R207 (Multiple endocrine neoplasia and other endocrine tumour syndromes).
Management & lifestyle
Management of Carney complex type 1 centres on systematic surveillance to detect tumours early, combined with treatment of specific complications as they arise. The NHS care pathway typically involves coordination between clinical genetics, endocrinology, and cardiology services. Annual echocardiography enables detection of cardiac myxomas before they cause symptoms, whilst regular biochemical screening assesses endocrine function. Some specialists recommend echocardiography every six to twelve months, particularly during childhood and young adulthood when myxomas most commonly develop.
Endocrine surveillance includes annual measurements of 24-hour urinary free cortisol or overnight dexamethasone suppression testing to screen for adrenal disease, along with assessment of growth hormone and insulin-like growth factor-1 levels. Thyroid ultrasonography and testicular examination in males form part of the surveillance protocol. When tumours are identified, treatment decisions balance the risks of intervention against the natural history of the specific lesion - cardiac myxomas generally require surgical removal due to embolic risk, whilst some endocrine tumours may be managed with medications or careful observation. Genetic counselling supports families in understanding the condition, arranging predictive testing for at-risk relatives where appropriate, and discussing reproductive options.
UK care pathway
Individuals with suspected or confirmed Carney complex type 1 access specialist care through the NHS Genomic Medicine Service. Referral to regional genetics services typically occurs following recognition of characteristic features by endocrinologists, cardiologists, or dermatologists. Clinical geneticists coordinate diagnostic genetic testing and arrange genetic counselling to discuss inheritance patterns and implications for family members.
The condition falls under PanelApp panel R207 (Multiple endocrine neoplasia and other endocrine tumour syndromes), enabling access to comprehensive genetic testing. Long-term management involves shared care between genetics services and relevant organ specialists, with surveillance protocols tailored to individual risk profiles. Genetic counsellors provide ongoing support for families, including discussion of predictive testing for relatives and reproductive options for affected individuals planning families.
Frequently asked questions
Will everyone with Carney complex develop heart tumours?
No, cardiac myxomas develop in some but not all people with Carney complex type 1, though regular echocardiography surveillance is recommended for all affected individuals to enable early detection if they do occur. The specific features and their timing vary considerably between individuals, even within the same family.
Can the skin spots in Carney complex be removed?
The lentigines themselves are benign and do not require treatment from a medical perspective. Some individuals choose cosmetic treatments such as laser therapy to reduce their appearance, though new spots may continue to develop over time. Discussion with a dermatologist can help explore options if the pigmentation causes concern.
How often do I need screening if I have Carney complex?
Surveillance protocols vary between centres but typically include annual echocardiography, yearly endocrine biochemistry screening, and periodic imaging of relevant organs. Your clinical genetics team and specialist clinicians will develop a personalised surveillance plan based on your specific features and family history.
Should my children be tested for Carney complex?
If you have Carney complex, each of your children has a 50% chance of inheriting the genetic variant. Predictive genetic testing is available for at-risk family members and can enable early surveillance if they carry the variant. Genetic counselling helps families consider the benefits and limitations of testing, including the timing of testing for children.
Is Carney complex the same as Carney triad?
No, these are distinct conditions despite similar names. Carney complex involves multiple endocrine tumours, cardiac myxomas, and skin pigmentation due to PRKAR1A variants, whilst Carney triad describes a different pattern of gastric, pulmonary, and adrenal tumours occurring together without a known inherited genetic cause.
References
- Peiling Yang S, Ngeow J. Familial non-medullary thyroid cancer: unraveling the genetic maze. Endocrine-related cancer. 2016. PMID: 27807061
- Dotto J, Nosé V. Familial thyroid carcinoma: a diagnostic algorithm. Advances in anatomic pathology. 2008. PMID: 18948764
- Nosé V. Familial non-medullary thyroid carcinoma: an update. Endocrine pathology. 2008. PMID: 18931957
- Carroll SL. Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms. Acta neuropathologica. 2012. PMID: 22160322
- Nosé V. Thyroid cancer of follicular cell origin in inherited tumor syndromes. Advances in anatomic pathology. 2010. PMID: 20966648
- Li Q, Lu P, Cui H. Multiple Giant Right Atrial Myxomas-The Carney Complex. JAMA cardiology. 2026. PMID: 42684730